GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » MetaStat Inc (OTCPK:MTST) » Definitions » Cyclically Adjusted Price-to-FCF

MetaStat (MetaStat) Cyclically Adjusted Price-to-FCF : (As of Jun. 23, 2024)


View and export this data going back to 2008. Start your Free Trial

What is MetaStat Cyclically Adjusted Price-to-FCF?

Shiller PE for Stocks: The True Measure of Stock Valuation


MetaStat Cyclically Adjusted Price-to-FCF Historical Data

The historical data trend for MetaStat's Cyclically Adjusted Price-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

MetaStat Cyclically Adjusted Price-to-FCF Chart

MetaStat Annual Data
Trend Feb09 Feb10 Feb11 Feb12 Feb13 Feb14 Feb15 Feb16 Feb17 Feb18
Cyclically Adjusted Price-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

MetaStat Quarterly Data
May13 Aug13 Nov13 Feb14 May14 Aug14 Nov14 Feb15 May15 Aug15 Nov15 Feb16 May16 Aug16 Nov16 Feb17 May17 Aug17 Nov17 Feb18
Cyclically Adjusted Price-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of MetaStat's Cyclically Adjusted Price-to-FCF

For the Biotechnology subindustry, MetaStat's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


MetaStat's Cyclically Adjusted Price-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, MetaStat's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where MetaStat's Cyclically Adjusted Price-to-FCF falls into.



MetaStat Cyclically Adjusted Price-to-FCF Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted Price-to-FCF takes the Free Cash Flow per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/FCF calculation. Because it considers this 10-year average, it's often referred to as the CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF.

MetaStat's Cyclically Adjusted FCF per Share for the quarter that ended in Feb. 2018 is calculated as:

For example, MetaStat's adjusted Free Cash Flow per Share data for the three months ended in Feb. 2018 was:

Adj_FreeCashFlowPerShare=Free Cash Flow per Share/CPI of Feb. 2018 (Change)*Current CPI (Feb. 2018)
=-0.078/105.0520*105.0520
=-0.078

Current CPI (Feb. 2018) = 105.0520.

MetaStat Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
200805 -1.212 91.399 -1.393
200808 -1.303 92.435 -1.481
200811 -0.152 89.624 -0.178
200902 0.000 89.527 0.000
200905 0.000 90.228 0.000
200908 0.000 91.063 0.000
200911 0.000 91.272 0.000
201002 0.000 91.445 0.000
201005 0.000 92.052 0.000
201008 0.000 92.108 0.000
201011 0.000 92.315 0.000
201102 0.000 93.373 0.000
201105 -0.325 95.337 -0.358
201108 -0.184 95.582 -0.202
201111 -0.290 95.449 -0.319
201202 -0.392 96.053 -0.429
201205 -0.475 96.961 -0.515
201208 -0.523 97.199 -0.565
201211 -0.555 97.133 -0.600
201302 -0.203 97.953 -0.218
201305 -0.503 98.282 -0.538
201308 -0.263 98.675 -0.280
201311 -0.356 98.334 -0.380
201402 -0.568 99.057 -0.602
201405 -0.366 100.373 -0.383
201408 -0.844 100.352 -0.884
201411 -0.404 99.635 -0.426
201502 -0.529 99.032 -0.561
201505 -0.552 100.333 -0.578
201508 -0.551 100.548 -0.576
201511 -0.321 100.135 -0.337
201602 -0.385 100.040 -0.404
201605 -0.227 101.355 -0.235
201608 -0.177 101.617 -0.183
201611 -0.144 101.829 -0.149
201702 -0.224 102.779 -0.229
201705 -0.132 103.256 -0.134
201708 -0.133 103.587 -0.135
201711 -0.165 104.072 -0.167
201802 -0.078 105.052 -0.078

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


MetaStat  (OTCPK:MTST) Cyclically Adjusted Price-to-FCF Explanation

Compared with the regular Price-to-Free-Cash-Flow, which works poorly for cyclical businesses, the Cyclically Adjusted Price-to-FCF smoothed out the fluctuations of free cash flow during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted Price-to-FCF should give similar results to regular Price-to-Free-Cash-Flow.


MetaStat Cyclically Adjusted Price-to-FCF Related Terms

Thank you for viewing the detailed overview of MetaStat's Cyclically Adjusted Price-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


MetaStat (MetaStat) Business Description

Industry
Traded in Other Exchanges
N/A
Address
27 Drydock Avenue, 2nd Floor, Boston, MA, USA, 02210
MetaStat Inc is a US-based biotechnology company which focuses on discovering and developing personalized therapeutic (Rx) and diagnostic (Dx) treatment solutions for cancer patients. The company focuses on development programs of the novel therapeutic product candidates that target the Mena protein isoform whereas the Companion Diagnostics program is focused on developing companion tests to be used in combination with cancer drugs, that provide essential information for the safe and effective use of a corresponding drug or biological product to improve patient outcome. It also develops a prognostic diagnostic program which is focused on developing diagnostic tests that predict the risk of future metastasis in cancer patients following the initial treatment of their primary tumor.
Executives
Daniel H Schneiderman officer: VP OF FINANCE AND SECRETARY 760 PARKSIDE AVE. SUITE 304, SUITE 207, BROOKLYN NY 11226
Jerome B Zeldis director 8767 E. VIA DE VENTURA, SUITE 190, SCOTTSDALE AZ 85258
Paul Billings director 11055 FLINTKOTE AVENUE, SUITE B, SAN DIEGO CA 92121
Richard J Berman director 305 COLLEGE ROAD EAST, PRINCETON NJ 08540
Martin J Driscoll director C/O JAVELIN PHARMACEUTICALS, INC., 125 CAMBRIDGE PARK DRIVE, CAMBRIDGE MA 02140
Oscar Bronsther director 4 AUTUMNWOOD COURT, THE WOODLANDS TX 77380
Johan M. Spoor director 500 BOYLSTON STREET, SUITE 1600, BOSTON MA 02116
David N Siegel director T-S CAPITAL PARTNERS, LLC, 1350 TREAT BOULEVARD, SUITE 400, WALNUT CREEK CA 94597
Warren C Lau director 2635 N. CRESCENT RIDGE DRIVE, THE WOODLANDS TX 77381
Patrick T Mooney director C/O SONTRA MEDICAL CORPORATION, 10 FORGE PARKWAY, FRANKLIN MA 02038
David M. Epstein director OSI PHARMACEUTICALS, INC., 41 PINELAWN ROAD, MELVILLE NY 11747
Richard W Perkins 10 percent owner 730 EAST LAKE STREET, WAYZATA MN 55391
Harvey Judkowitz director 10220 SW 124 ST, MIAMI FL 33176

MetaStat (MetaStat) Headlines

No Headlines